Celsion Presents Combined Clinical Data from Two Phase I Trials

Celsion Corporation

today announced the presentation of the combined clinical study results from the Company's Phase I DIGNITY study and the Duke University sponsored Phase I trial of ThermoDox® plus hyperthermia in Breast Cancer Recurrences at the Chest Wall (BCRCW) at the 2013 San Antonio Breast Cancer Conference during Poster Session #4 on Friday, December 13, 2013 between 7:30 am to 9:00 am (local time). The poster, titled "Novel Targeted Therapy for Breast Cancer Chest Wall Recurrence: Low Temperature Liposomal Doxorubicin and Mild Local Hyperthermia " was presented by Professor Hope S. Rugo, MD, from the University of California, San Francisco Comprehensive Cancer Center.  A copy of the poster presentation is available on the Company's website at www.celsion.com.   The two similarly designed Phase I studies enrolled patients with highly resistant tumors found on the chest wall and who had progressed on previous therapy including chemotherapy, radiation therapy and hormone therapy.  Unresectable BCRCW is very difficult to treat and often responds poorly to radiation and systemic chemotherapy.  These patients can suffer from